Ulcerative Colitis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Ulcerative Colitis stocks.

Ulcerative Colitis Stocks Recent News

Date Stock Title
May 17 BHC Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
May 17 HCM HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
May 16 VTYX Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
May 16 ROIV Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
May 16 GLPG Galapagos creates new subscription right plans
May 16 VTYX Ventyx Biosciences gets new operations chief
May 16 VTYX Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
May 15 GLPG Galapagos, BCA to collaborate on CAR-T cell therapy production
May 15 GLPG Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
May 15 BHC RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich
May 15 BHC Bausch Health Announces 2024 Annual Meeting of Shareholder Results
May 14 BHC Bausch issues update on Xifaxan patent dispute with Norwich
May 14 BHC Bausch Health Down 6.6% In US After Hours As Updates Related to Norwich XIFAXAN Matters
May 14 BHC Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
May 14 PTGX Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
May 14 LXRX New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
May 14 HCM HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
May 14 HCM HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
May 13 BHC RBC Noes Bausch Health Filing For Rehearing in Appellate Court
May 13 MCRB Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript
Ulcerative Colitis

Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur. Often, symptoms come on slowly and can range from mild to severe. Symptoms typically occur intermittently with periods of no symptoms between flares. Complications may include megacolon, inflammation of the eye, joints, or liver, and colon cancer.The cause of UC is unknown. Theories involve immune system dysfunction, genetics, changes in the normal gut bacteria, and environmental factors. Rates tend to be higher in the developed world with some proposing this to be the result of less exposure to intestinal infections, or to a Western diet and lifestyle. The removal of the appendix at an early age may be protective. Diagnosis is typically by colonoscopy with tissue biopsies. It is a kind of inflammatory bowel disease (IBD) along with Crohn's disease and microscopic colitis.Dietary changes, such as maintaining a high-calorie diet or lactose-free diet, may improve symptoms. Several medications are used to treat symptoms and bring about and maintain remission, including aminosalicylates such as mesalazine or sulfasalazine, steroids, immunosuppressants such as azathioprine, and biologic therapy. Removal of the colon by surgery may be necessary if the disease is severe, does not respond to treatment, or if complications such as colon cancer develop. Removal of the colon and rectum can cure the disease.Together with Crohn's disease, about 11.2 million people were affected as of 2015. Each year it newly occurs in 1 to 20 per 100,000 people, and 5 to 500 per 100,000 individuals are affected. The disease is more common in North America and Europe than other regions. Often it begins in people aged 15 to 30 years, or among those over 60. Males and females appear to be affected in equal proportions. It has also become more common since the 1950s. Together, ulcerative colitis and Crohn's disease affect about a million people in the United States. With appropriate treatment the risk of death appears the same as that of the general population. The first description of ulcerative colitis occurred around the 1850s.

Browse All Tags